Equities

Lumos Diagnostics Holdings Ltd

Lumos Diagnostics Holdings Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.045
  • Today's Change-0.001 / -2.17%
  • Shares traded873.92k
  • 1 Year change+200.00%
  • Beta--
Data delayed at least 20 minutes, as of May 20 2024 03:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company’s products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.

  • Revenue in AUD (TTM)12.30m
  • Net income in AUD-13.21m
  • Incorporated2018
  • Employees--
  • Location
    Lumos Diagnostics Holdings Ltd100 Albert Rd, Level 4SOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 39087-1598
  • Websitehttps://lumosdiagnostics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oncosil Medical Ltd355.30k-11.71m16.59m2.00--2.56--46.68-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Auscann Group Holdings Ltd2.05m-9.44m17.64m27.00------8.61-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Chimeric Therapeutics Ltd0.00-11.31m17.98m----1.10-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Acrux Ltd14.46m-709.00k18.32m43.00--3.24--1.27-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.70-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Rhythm Biosciences Ltd157.67k-8.63m19.39m----14.17--122.98-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Immuron Ltd3.58m-3.88m20.52m6.00--1.17--5.74-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
BPH Energy Ltd345.67k894.65k20.85m2.00k19.390.9375--60.330.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Noxopharm Ltd3.90m-12.13m21.04m1.00k--3.20--5.39-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
LBT Innovations Limited2.00m-21.38m21.45m17.00--7.90--10.70-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Lumos Diagnostics Holdings Ltd12.30m-13.21m22.14m----1.60--1.80-0.0355-0.03550.03490.02870.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Syntara Ltd9.83m-14.26m23.88m107.00--2.65--2.43-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
LTR Pharma Ltd-100.00bn-100.00bn24.99m----7.88----------0.0451----------------------------0.00---100.00---41.65------
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
BCAL Diagnostics Ltd3.67m-5.00m26.49m----4.35--7.21-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
Cann Group Ltd16.45m-29.28m27.12m40.00--0.5339--1.65-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Data as of May 20 2024. Currency figures normalised to Lumos Diagnostics Holdings Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

13.64%Per cent of shares held by top holders
HolderShares% Held
Perennial Value Management Ltd.as of 15 Jan 202465.64m13.64%
Data from 31 Jul 2021 - 31 Jul 2021Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.